biotech peptides bpc-157 coa – Research Peptide BPC 157 | Gastric Pentadecapeptide

The evidence was based on experimental data only briefly described in the patent and included models of: gastric ulcers, heart damage, liver damage, pancreatic injury, kidney damage, experimental diabetes, fever, edema, rhinitis, bone fracture, burns, skin wounds, hypersensitivity reactions, pupil dilation, colon injury, tumour growth, radiation injury, red blood cell development, fertility and lactation, tooth damage, several types of central and peripheral nerve damage, and survival from infection with Trichinosis (i.e., tapeworms) as well as several viruses

Repairs stomach lining and intestinal barrier

Complimentary Online TeleHealth Consultation

Sterile, non-pyrogenic solution with 0.9% benzyl alcohol for safe medication dilution and reconstitution